Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Engels EA et al. Bone Marrow Transplant. 2014 Sep 29. doi: 10.1038/bmt.2014.213. [Epub ahead of print]. Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study. Kashyap R et al. Asia Pac J Clin Oncol. 2014 Sep 22.…
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. Benboubker L et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Moreau P et al. Br J Haematol. 2014 Sep 19. doi: 10.1111/bjh.13128. [Epub ahead of print]. Bortezomib, thalidomide and…
Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Higo H et al. Intern Med. 2014;53(16):1809-12. Epub 2014 Aug 15. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Kourelis TV et al. Am J Hematol. 2014 Aug 11. doi: 10.1002/ajh.23827. [Epub ahead of print]. Immunophenotypic analysis of…
Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. Hultcrantz M et al. Cancer Med. 2014 Aug 26. doi: 10.1002/cam4.316. [Epub ahead of print]. Bortezomib in multiple myeloma: systematic review and clinical considerations. Kouroukis TC et al. Curr Oncol. 2014 Aug;21(4):e573-603. doi: 10.3747/co.21.1798. Novel Agents In Cns Myeloma Treatment.…
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.Iyer SP et al. Br J Haematol. 2014 Aug 19. doi: 10.1111/bjh.13056. [Epub ahead of print].Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis.Frediani…
Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. Kosturakis AK et al. J Clin Oncol. 2014 Aug 25. pii: JCO.2013.54.5418. [Epub ahead of print]. Hepatitis B virus reactivation in multiple myeloma patients receiving bortezomib-containing regimens followed by autologous stem cell transplantation. Li J et al. Leuk…
Update of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Mateos MV et al. Blood. 2014 Aug 7. pii: blood-2014-05-573733. [Epub ahead of print]. Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood…
These updated guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the diagnosis and management of myeloma patients. They should be read in conjunction with the BCSH Guidelines on the supportive care of myeloma patients. Bird et al.…
These guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the supportive care of myeloma patients and should be read in conjunction with the BCSH Guidelines for the diagnosis and management of myeloma.
This paper, written by an expert panel on behalf of the European Myeloma Network, reviews the available evidence and provides recommendations for the management of newly diagnosed myeloma patients.